Position in GANX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$21,518
+$954 QoQ
Shares Held
10,600
0.0% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#38
of 49 holders
Holding Since
Mar 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NewEdge Advisors, LLC holds $47,755,733 across 102 Biotechnology names. GANX ranks #54 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
18,435 | $9,157,217 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11,911 | $7,426,984 | |
| 3 | NUVB |
Nuvation Bio Inc.
|
1,231,733 | $6,996,243 | |
| 4 | INCY |
Incyte Corp
|
34,605 | $3,922,822 | |
| 5 | PHAT |
Phathom Pharmaceuticals, Inc.
|
203,962 | $2,212,987 | |
| 6 | EXEL |
Exelixis, Inc.
|
32,532 | $1,770,066 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
27,287 | $1,561,362 | |
| 8 | RPRX |
Royalty Pharma plc
|
21,597 | $1,210,943 |
All Filings in GANX
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $21,518 | 10,600 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $20,564 | 10,600 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $34,132 | 10,600 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $18,762 | 10,600 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $19,080 | 10,600 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $20,246 | 10,600 | Shares | Sole | 2025-05-15 | |
| 2024-03-31 | $848 | 225 | Shares | Sole | 2024-05-14 | |
| 2023-09-30 | $36,244 | 11,050 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $49,504 | 11,050 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $50,610 | 10,500 | Shares | Sole | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||